DK2214480T3 - Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter - Google Patents

Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter

Info

Publication number
DK2214480T3
DK2214480T3 DK08853916.8T DK08853916T DK2214480T3 DK 2214480 T3 DK2214480 T3 DK 2214480T3 DK 08853916 T DK08853916 T DK 08853916T DK 2214480 T3 DK2214480 T3 DK 2214480T3
Authority
DK
Denmark
Prior art keywords
nash
treatment
methods
nonalcoholic steatohepatitis
cysteamine products
Prior art date
Application number
DK08853916.8T
Other languages
English (en)
Inventor
Ranjan Dohil
Jerry Schneider
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2214480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK2214480T3 publication Critical patent/DK2214480T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK08853916.8T 2007-11-30 2008-11-28 Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter DK2214480T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US8539708P 2008-07-31 2008-07-31
PCT/US2008/085064 WO2009070781A1 (en) 2007-11-30 2008-11-28 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Publications (1)

Publication Number Publication Date
DK2214480T3 true DK2214480T3 (da) 2013-07-08

Family

ID=40679016

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08853916.8T DK2214480T3 (da) 2007-11-30 2008-11-28 Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter

Country Status (25)

Country Link
US (5) US7994226B2 (da)
EP (2) EP2636404B1 (da)
JP (3) JP5583022B2 (da)
KR (1) KR20100091219A (da)
CN (2) CN104825430B (da)
AR (1) AR069500A1 (da)
AU (1) AU2008329628B2 (da)
BR (1) BRPI0819690B8 (da)
CA (1) CA2706768C (da)
CL (1) CL2008003582A1 (da)
CY (1) CY1114126T1 (da)
DK (1) DK2214480T3 (da)
ES (1) ES2417179T3 (da)
HR (1) HRP20130590T1 (da)
IL (2) IL205909B (da)
MX (2) MX360827B (da)
MY (1) MY156316A (da)
NZ (1) NZ585732A (da)
PL (1) PL2214480T3 (da)
PT (1) PT2214480E (da)
RU (1) RU2498795C2 (da)
SG (1) SG10201403200RA (da)
TW (2) TWI535435B (da)
WO (1) WO2009070781A1 (da)
ZA (1) ZA201003670B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3659588A1 (en) 2006-01-27 2020-06-03 The Regents of The University of California Enterically coated cysteamine and salts thereof
TWI535435B (zh) * 2007-11-30 2016-06-01 美國加利福尼亞大學董事會 使用半胱胺產物治療非酒精性脂肪肝炎（ｎａｓｈ）之方法
WO2011145340A1 (ja) * 2010-05-19 2011-11-24 興和株式会社 非アルコール性脂肪性肝炎の予防及び／又は治療剤
US20110300190A1 (en) * 2010-06-08 2011-12-08 Krisani Biosciences (P) Ltd Compound, composition and uses thereof
CN103108634B (zh) * 2010-07-28 2015-08-12 幽兰化学医药有限公司 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物
WO2014045293A1 (en) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
US20130085075A1 (en) * 2011-06-06 2013-04-04 Meso Scale Technologies, Llc Diagnostic methods for liver disorders
WO2013040316A1 (en) * 2011-09-16 2013-03-21 Galectin Therapeutics, Inc. Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
BR112014009789A2 (pt) * 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
CA2851387A1 (en) * 2011-11-22 2013-05-30 The Regents Of The University Of California Cysteamine and/or cystamine for treating ischemic injury
WO2013149148A2 (en) * 2012-03-29 2013-10-03 Halo Therapeutics, Llc Dosage forms of halofuginone and methods of use
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
AR096628A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
KR102006247B1 (ko) * 2014-04-18 2019-08-01 주식회사 엘지화학 지방간 질환의 예방 또는 치료용 조성물
AU2016226906B2 (en) * 2015-03-03 2021-06-10 KOHJIN Life Sciences Co., Ltd. Composition for improving or preventing nonalcoholic fatty liver
JP2018525350A (ja) 2015-07-02 2018-09-06 ホライズン オルファン エルエルシー Ａｄｏ耐性システアミン類似体およびその使用
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
PL3634411T3 (pl) * 2017-06-08 2024-03-11 N-Gene Research Laboratories Inc. Sposób leczenia niealkoholowego stłuszczeniowego zapalenia wątroby (NASH) i zapobiegania indukowanemu NASH rakowi wątrobowokomórkowemu (HCC)
WO2019046659A1 (en) * 2017-08-30 2019-03-07 First Fruits Business Ministry, Llc COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
ES3024932T3 (en) * 2017-09-20 2025-06-05 Thiogenesis Therapeutics Inc Compounds for the treatment of cysteamine sensitive disorders
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
EP3946298A4 (en) * 2019-03-26 2023-01-25 The Regents of the University of California Substituted amino-thiol and amino-disulfide compounds, and uses thereof
JP2022542840A (ja) * 2019-07-19 2022-10-07 フィルトリシン， インコーポレイテッド がん処置および代謝介入療法および他の使用のための組成物、方法、キットならびにシステム
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用
CN116546981A (zh) * 2020-12-18 2023-08-04 雀巢产品有限公司 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
CN118489805B (zh) * 2024-05-31 2026-04-21 杭州康德权饲料有限公司 半胱胺或其盐在制备预防和改善蛋鸡脂肪肝的饲料添加剂中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20030137125A1 (en) * 2000-02-14 2003-07-24 Len Booysen Stabilizer unit
CN1144585C (zh) 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
CA2466869C (en) 2001-11-29 2010-01-19 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
CA2472678C (en) 2002-01-04 2013-12-03 Sound Pharmaceuticals Incorporated Otoprotectant compositions of glutathione peroxidase mimics for ameliorating hearing loss
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
CN100391448C (zh) * 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
US7442720B2 (en) 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
WO2005092914A1 (en) * 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
WO2005107730A2 (en) * 2004-05-03 2005-11-17 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
CN101146767A (zh) 2005-01-05 2008-03-19 M·A·K·阿布达拉 牛磺酸的合成、制备以及作为药物的用途
US8822535B2 (en) * 2005-04-20 2014-09-02 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
CA2634940A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
EP3659588A1 (en) * 2006-01-27 2020-06-03 The Regents of The University of California Enterically coated cysteamine and salts thereof
WO2007121545A1 (en) * 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
US20090304704A1 (en) 2006-05-03 2009-12-10 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
JPWO2008093764A1 (ja) 2007-02-02 2010-05-20 株式会社カネカ 糖尿病予防または治療用組成物
TWI535435B (zh) * 2007-11-30 2016-06-01 美國加利福尼亞大學董事會 使用半胱胺產物治療非酒精性脂肪肝炎（ｎａｓｈ）之方法

Also Published As

Publication number Publication date
PT2214480E (pt) 2013-07-23
MY156316A (en) 2016-02-11
TWI535435B (zh) 2016-06-01
JP2014237670A (ja) 2014-12-18
WO2009070781A1 (en) 2009-06-04
IL205909B (en) 2018-05-31
TWI478710B (zh) 2015-04-01
MX2010005921A (es) 2010-06-11
US20160143865A1 (en) 2016-05-26
AU2008329628B2 (en) 2014-06-26
US20120015005A1 (en) 2012-01-19
EP2214480B1 (en) 2013-03-27
KR20100091219A (ko) 2010-08-18
IL205909A0 (en) 2010-11-30
EP2214480A4 (en) 2010-09-29
JP6121951B2 (ja) 2017-04-26
BRPI0819690B8 (pt) 2021-05-25
CL2008003582A1 (es) 2009-04-03
US20130183351A1 (en) 2013-07-18
CY1114126T1 (el) 2016-07-27
TW200927093A (en) 2009-07-01
IL254586A0 (en) 2017-11-30
EP2636404A2 (en) 2013-09-11
TW201513855A (zh) 2015-04-16
HK1141945A1 (en) 2010-11-26
JP5583022B2 (ja) 2014-09-03
CA2706768C (en) 2016-06-28
CN101932238B (zh) 2015-04-08
EP2214480A1 (en) 2010-08-11
NZ585732A (en) 2012-02-24
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
EP2636404A3 (en) 2013-10-16
BRPI0819690B1 (pt) 2019-07-30
CA2706768A1 (en) 2009-06-04
CN101932238A (zh) 2010-12-29
PL2214480T3 (pl) 2013-11-29
US9511038B2 (en) 2016-12-06
SG10201403200RA (en) 2014-10-30
AR069500A1 (es) 2010-01-27
AU2008329628A1 (en) 2009-06-04
JP2017165735A (ja) 2017-09-21
US10307386B2 (en) 2019-06-04
MX360827B (es) 2018-11-16
US8263662B2 (en) 2012-09-11
JP2011505375A (ja) 2011-02-24
RU2498795C2 (ru) 2013-11-20
EP2636404B1 (en) 2019-03-20
US20100303870A1 (en) 2010-12-02
HRP20130590T1 (en) 2013-08-31
US9149448B2 (en) 2015-10-06
BRPI0819690A2 (pt) 2014-10-07
US20170304233A1 (en) 2017-10-26
ES2417179T3 (es) 2013-08-06
US7994226B2 (en) 2011-08-09
RU2010126631A (ru) 2012-01-10
ZA201003670B (en) 2011-08-31

Similar Documents

Publication Publication Date Title
IL254586A0 (en) Methods for treating NASH using cystamine products
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2076540T3 (da) Hidtil ukendte anti-cd38-antistoffer til behandling af cancer
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2001892T3 (da) Imidazolthiazolforbindelser til behandling af proliferative sygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2240137T3 (da) Apparat til behandling af fedme
ZA200906129B (en) Compounds for the treatment of hepatitis c
DK2178863T3 (da) Fremgangsmåde til syntetisering af anvendelige forbindelser til behandling af hepatitis C
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
IL228988A (en) Antibody preparations for the treatment of vaccine-related diseases
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
ZA201101739B (en) Compounds for the treatment of hepatitis c
DK2068874T3 (da) Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
DK2114386T3 (da) Farmaceutisk sammensætning til behandling af diabeteskomplikationer
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
DK2209784T3 (da) Forbindelser til behandling af hepatitis C